Related Experiment Video

Updated: Aug 30, 2026

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity

Mark S Duxbury1, Hiromichi Ito, Eric Benoit

  • 1Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Biochemical and Biophysical Research Communications
|November 19, 2003
PubMed

Insights

Inhibiting focal adhesion kinase (FAK) enhances gemcitabine chemotherapy effectiveness in pancreatic cancer cells. Suppressing FAK also reduces Akt activity, potentially improving treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Focal adhesion kinase (FAK) plays a crucial role in cellular processes like signaling, migration, apoptosis, and cell cycle progression.
  • Pancreatic adenocarcinoma is often associated with chemoresistance, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To investigate the role of FAK in gemcitabine chemoresistance in pancreatic cancer cells.
  • To evaluate the effect of FAK inhibition on gemcitabine-induced cytotoxicity in vitro and in vivo.

Main Methods:

  • FAK expression was analyzed using Western and Northern blots.
  • FAK expression was suppressed using small interfering RNA (siRNA).
  • Gemcitabine-induced cytotoxicity and apoptosis were quantified; Akt activity was assessed via kinase assay. In vivo efficacy was tested in a xenograft model.

Main Results:

  • FAK siRNA potentiated gemcitabine-induced cytotoxicity both in vitro and in vivo.
  • FAK inhibition did not affect cellular proliferation or apoptosis in the absence of gemcitabine.
  • FAK siRNA treatment led to suppressed Akt activity, potentially contributing to chemosensitization.

Conclusions:

  • FAK is a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma.
  • Inhibiting FAK expression represents a potential therapeutic strategy to enhance gemcitabine efficacy in pancreatic cancer.

More Related Videos

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...